|
|
News Breaks
|
January 25, 2012
|
| 08:06 EDT |  | ACTC |
| theflyonthewall.com: | ACT announces new patient with Stargardt's undergoing transplantation | | Advanced Cell Technology announced the dosing of an additional patient in its Phase 1/2 trial for Stargardt's macular dystrophy using retinal pigment epithelial cells derived from human embryonic stem cells. The patient was treated on Tuesday by Steven Schwartz, M.D., Ahmanson Professor of Ophthalmology at the David Geffen School of Medicine at UCLA and retina division chief at UCLA's Jules Stein Eye Institute. The patient successfully underwent the outpatient transplantation surgery and is recovering uneventfully. :theflyonthewall.com |
|
|
News For ACTC From The Last 14 Days Check below for free stories on ACTC the last two weeks.
| Sign up for a free trial to see the rest of the stories you've been missing. |
There are no results for these search parameters.
|
|
|
|
